Emily Singer commissions and edits scientist-written content and develops new resources for the community. She joined The Transmitter in 2023 and has previously held a variety of editorial roles at the Simons Foundation, including editor for neuroscience collaborations, and senior biology writer and contributing editor at Quanta Magazine. Before joining the foundation, she was biomedical editor at Technology Review.
Emily Singer
Chief opinion editor
The Transmitter
From this contributor
How insights from network theory can boost interdisciplinary efforts
By
Emily Singer
23 February 2026 | 0 min watch
Parents turn their skills to furthering autism research
By
Emily Singer
9 May 2013 | 7 min read
Gender differences take center stage at autism conference
By
Emily Singer
4 May 2013 | 6 min read
Education
- Certificate in science communication, University of California, Santa Cruz
- B.A. in biology, University of California, Santa Cruz
Fellowships
- AAAS Mass Media Fellowship
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read